HIV

Top content from CROI 2025 focused on COVID-19 and HIV, including the safety of a vaccine in people taking antiretroviral therapy.

The HIV chatbot was noninferior in increasing self-testing compared with the real-time support by human administrators.

Individuals told their absolute risk of HIV had higher interest in pre-exposure prophylaxis (PrEP) compared with those told relative risk.

Men who have sex with men (MSM) expressed interest in both monthly oral pills and injections every 6 months to prevent HIV.

Topline results find that single-tablet regimen of bictegravir/lenacapavir had noninferior efficacy when patients switched from multitablet regimens in HIV.

The efficacy of immune checkpoint inhibitors was found in patients with both HIV and non–small cell lung cancer (NSCLC), though more inclusion of people with HIV is needed in future studies.

Young and frequently incarcerated individuals living with HIV require discharge planning and post release support to maintain viral suppression outcomes.

Researchers found more local pharmacies than facilities that prescribed pre-exposure prophylaxis (PrEP) in areas of high case load.

The government should focus on keeping up the funding for HIV to continue to innovate in this space, potentially eliminating the virus altogether.

Opioids were more likely to be prescribed to Medicare beneficiaries living with HIV, which led to opioid use disorder (OUD).

Funding cuts for research intended to make treatment and cures available and accessible for patients with HIV could affect HIV care in the long term.

Public health must address emotional and structural inequities, emphasizes Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health.

An epidemic resurgence is possible in Zambia should rapid restoration of HIV services not be conducted.

Several actions taken by the current administration may affect the landscape of prevention of HIV, prompting an analysis of these effects.

Any potential reduction in access to pre-exposure prophylaxis (PrEP) would increase both cost and the number of diagnoses of HIV.

Despite higher burden of metabolic issues, individuals with HIV were not more metabolically ill.

Net health care costs would also increase by billions of dollars should pre-exposure prophylaxis become less accessible.

A reduction in HIV incidence is possible with more structured choices for pre-exposure and postexposure prophylaxis being offered to patients at risk of HIV.

Bone density was found to be lower in those diagnosed with HIV vs those who were HIV-negative.

Reducing the deferral period from 12 months to 3 months for those with high-risk behaviors did not increase the incidence of infectious diseases like HIV and hepatitis B appearing in donated blood.

New abstracts from the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025 found that ACC017 showed promise in its use as an antiretroviral therapy.

Patients had better linkage to care for HIV and HIV was more frequently diagnosed when it was tested alongside other sexually transmitted infections (STIs), such as chlamydia and gonorrhea.

Women with HIV who were Hispanic, Haitian, or African American were more likely to adhere to antiretroviral therapy (ART) if they had culturally sensitive care.

Older survivors of HIV require ethical safeguards and autonomy to feel comfortable participating in end-of-life research for a cure for HIV.

Couples that were made up of 2 transgender women were less likely to contract HIV compared with couples that were made up of a transgender woman and a cisgender man.

Young transgender adults had increased adherence to long-acting pre-exposure prophylaxis (PrEP) when adherence was confirmed via blood testing and incentives were delivered in cash.

High stigma due to HIV was also associated with depression and drug use, making the reduction in stigma vital for improving the care of women with HIV.

The clearance rates for those coinfected with HIV and hepatitis C virus (HCV) are still higher than those with HCV alone.

Patients with HIV had lower adherence to pre-exposure prophylaxis (PrEP) if they lived in areas with the lowest disadvantage.

Quality of life in people living with HIV was lower in those who had weight gain from adherence to antiretroviral therapy.